A total of 65 patients with clinically significant diagnoses of remitting multiple sclerosis in the stage of remission were studied. Neurological status was investigated with assessment on the FS and EDSS scales, with neuropsychological testing, and MRI scans (1.5 T). The severity of brain atrophy (in terms of the parenchyma volume) and the total volume of foci on T2 images were assessed as proportions of intracerebral volume. The severity of neurological deficit depended on the volume of intratentorial focal lesions and the level of brain atrophy. Cognitive disorders were identified in 89% of patients, and the severity of these was associated with the level of atrophy and the volume of foci on T2 images in the dominant hemisphere.
Using multicolor flow cytometry four main Th17 subsets were identified within total CCR6-expressing Th cell in peripheral blood from patients with multiply sclerosis (MS, n = 26) and healthy control subjects (HC, n = 44). MS showed significantly higher frequencies of CCR6+DP and “classical” Th17 subsets, while the level of Th17.1 was significantly decreased if compared to HC. Correlation analysis revealed a significant relationship between the decrease of CCR6+DN Th17 subset and EDSS worsening (r = -0.456, p = 0.022). The area under the ROC curve (AUC) for the percentage of “classical” Th17 within CCR6+ Th as a predictor of MS was 0.948 (0.882 to 1.014, p < 0.001) and for Th17.1 cells - 0.937 (0.863 to 1.011, p < 0.001). The optimal cutoff value for percentage of “classical” Th17 for predicting MS was 31.55% within CCR6+ Th cells with 88.0% sensitivity and 95.45% specificity, while for Th17.1 - 38.66% within CCR6+ Th cells with 88.0% sensitivity and 95.45% specificity. Our data indicate that the relative numbers of “classical” Th17 and Th17.1 within CCR6+ Th cells were effective in discrimination between MS and HC groups.
Обследовано 40 пациентов, перенесших COVID-19 ассоциированную пневмонию с резидуальными признаками астенического синдрома. У пациентов, получавших дополнительно к стандартной реабилитационной программе цитофлавин (20 мл внутривенно капельно ежедневно 10 дней, затем внутрь по 2 таблетки 2 раза в день, 25 дней) к 35 дню исследования наблюдали уменьшение выраженности астении по шкалам ШАС в 2,57 раза и по MFI 2,2 раза (p ≤ 0,05) в отличие от контрольной группы. При оценке когнитивных функций и психоэмоционального состояния в основной группе средние результаты тестирования соответствовали референсным значениям к концу терапии, в то время как в контрольной группе большая часть пациентов (от 60 до 90 % в зависимости от теста) не достигла нормальных показателей. В основной группе, в отличие от контрольной, к концу лечения наблюдалось улучшение качества жизни в 1,5 раза и качества сна в 3,85 раза (p ≤ 0,05).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.